MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Xience V (Promus) Drug-Eluting Coronary Stent
Design features, preclinical data, and clinical outcomes.
By Krishna Sudhir, MD, PhD, FRACP, FACC; David R. Rutledge, Pharm D, FAHA, FCCP; Alena Pechonkina, MD; and Chuck Simonton, MD, FACC, FSCAI
Abiomed's Impella ECP Granted FDA Breakthrough Device Designation
August 18, 2021—Abiomed announced that the FDA has granted Breakthrough Device designation to the company's Impella ECP expandable percutaneous heart pump.
Survival Rates With Abiomed's Impella Heart Pump Evaluated in Japanese Registry
July 30, 2020—Abiomed announced that a 3-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump showed that use of the device is associated with a 77% survival rate at 30 days in acute myocardial infarction (AMI) cardiogenic shock patients.
Abiomed Begins RECOVER IV RCT of Impella Device for AMI Cardiogenic Shock
November 27, 2023—Abiomed, part of Johnson & Johnson MedTech, announced the first patient has been enrolled in the company’s landmark RECOVER IV randomized controlled trial (RCT).
